WCN24-752 CONCOMITANT SPARSENTAN AND SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2is) IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN) IN THE PROTECT OPEN-LABEL EXTENSION (OLE)

WCN24-752 CONCOMITANT SPARSENTAN AND SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2is) IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN) IN THE PROTECT OPEN-LABEL EXTENSION (OLE)

Saved in:

Bibliographic Details
Main Authors:	Radko Komers, Laura Kooienga, Robert Malecki, Alex Mercer, Nuhira Ahmed Masthan Ahmed, Priscila Preciado
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924003796
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN24-774 PRELIMINARY FINDINGS FROM THE PHASE 2 EPPIK STUDY OF SPARSENTAN IN PEDIATRIC PATIENTS WITH SELECTED PROTEINURIC GLOMERULAR DISEASES
by: Radko Komers, et al.
Published: (2024-04-01)

WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN24-2352 Improved Proteinuria Reduction with the use of Sparsentan and Targeted Release Budesonide in advanced IgAN
by: Neeharik Mareedu, et al.
Published: (2024-04-01)

WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL
by: Chee Kay Cheung, et al.
Published: (2025-02-01)

WCN24-773 SPARSENTAN AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY: PRELIMINARY FINDINGS FROM THE SPARTAN TRIAL
by: Chee Kay Cheung, et al.
Published: (2024-04-01)

WCN25-1898 IMPLICATIONS OF PROTEINURIA REMISSION ON ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) TRAJECTORY IN PATIENTS (Pts) WITH IgA NEPHROPATHY (IgAN) IN PROTECT
by: Bruce Hendry, et al.
Published: (2025-02-01)

Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study
by: Howard Trachtman, et al.
Published: (2024-04-01)

WCN25-1585 A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

ALDH2 mediates the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on improving cardiac remodeling
by: Han Liu, et al.
Published: (2024-10-01)

Effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on the clinical outcomes of patients with diabetic atrial fibrillation
by: Selim Aydemir, et al.
Published: (2024-12-01)

Burden of corticosteroid therapy in patients with immunoglobulin A nephropathy (IgAN): a systematic literature review
by: Sarah N. Ali, et al.
Published: (2025-05-01)

WCN24-1868 ASSIST: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER TRIAL OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN) ON SGLT2I
by: Irene L. Noronha, et al.
Published: (2024-04-01)

Real-world assessment of sparsentan’s drug safety framework
by: Wenjing Fu, et al.
Published: (2025-12-01)

Commentary on “Assessment of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other antidiabetic agents in Alzheimer’s disease: A population-based study”
by: Feng Chen, et al.
Published: (2025-05-01)

Application of TL16C752 in Power Dispatching of Photovoltaic Inverter
by: ZHAO Xianggui, et al.
Published: (2013-01-01)

WCN24-1063 The role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in Diabetic Nephropathy and Non Diabetic Renal Disease in Diabetes Mellitus type2 Patients
by: Maru Navarro, et al.
Published: (2024-04-01)

WCN25-52 EPIDEMIOLOGY OF IMMUNOGLOBULIN A NEPHROPATHY (IgAN) AND OCCURRENCE OF PROTEINURIA IN CHINA: EVIDENCE FROM SYSTEMATIC REVIEW AND META-ANALYSIS
by: Zhaoxin Chen, et al.
Published: (2025-02-01)

Study protocol of the multicentre, randomised, triple-blind, placebo-controlled MERCURI-2 trial: promoting effective renoprotection in cardiac surgery patients by inhibition of sodium glucose cotransporter (SGLT)-2
by: Frederique Paulus, et al.
Published: (2025-05-01)

WCN24-846 SPARSENTAN RECEPTOR OCCUPANCY MODELING, CLINICAL ACTIONS, AND SAFETY
by: Bruce Hendry, et al.
Published: (2024-04-01)

Correction: Study protocol of the multicentre, randomised, triple-blind, placebo-controlled MERCURI-2 trial: promoting effective renoprotection in cardiac surgery patients by inhibition of sodium glucose cotransporter (SGLT)-2
Published: (2025-08-01)

Role of NLRP3 Inflammasome in Heart Failure Patients Undergoing Cardiac Surgery as a Potential Determinant of Postoperative Atrial Fibrillation and Remodeling: Is SGLT2 Cotransporter Inhibition an Alternative for Cardioprotection?
by: Rodrigo L. Castillo, et al.
Published: (2024-11-01)

WCN24-2219 TRF-BUDESONIDE AND SPARSENTAN AS AN INITIAL THERAPY FOR PRIMARY IgA NEPHRITIS
by: Neeharik Mareedu, et al.
Published: (2024-04-01)

Ks. Janusz Czerski, Pierwszy List do Koryntian, Wydawnictwo TUM, Wrocław 2009, ss. 752
by: Krzysztof Wojtkowiak
Published: (2010-12-01)

Genetic variability in sodium-glucose cotransporter 2 and glucagon-like peptide 1 receptor effect on glycemic and pressure control in type 2 diabetes patients treated with SGLT2 inhibitors and GLP-1RA in the everyday clinical practice
by: Gašper Tonin, et al.
Published: (2025-07-01)

Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
by: A. M. Mkrtumyan, et al.
Published: (2021-09-01)

Response to letter to the editor: Letter by Chen et al. regarding article, “Assessment of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other antidiabetic agents in Alzheimer's disease: A population-based study”
by: Mar Garcia – Zamora, et al.
Published: (2025-05-01)

WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

SGLT2-Inhibition in Patients With Alport Syndrome
by: Jan Boeckhaus, et al.
Published: (2024-12-01)

Is cancer incidence modified by SGLT2 inhibitors?
by: Lev M. Berstein
Published: (2019-10-01)

Ole Henrik Magga gielladutkin
by: Jussi Ylikoski
Published: (2020-02-01)

Ole Hallesby og fascismen
by: Hans Bringeland
Published: (2022-12-01)

Mass balance of IGAN Glacier (the Polar Urals) in 2018–2023
by: G. A. Nosenko, et al.
Published: (2025-02-01)

First-Time Usage of SGLT2 Inhibitors in Patients With Type 2 Diabetes Who Are Fasting Ramadan: Efficacy and Safety
by: Hany Ahmed Muhammed Khalil, et al.
Published: (2025-01-01)

Sodium-glucose cotransporter 2 inhibitors as potential anticancer agents
by: E. R. Radkevich, et al.
Published: (2025-05-01)

Sodium-glucose cotransporter 2 inhibitor for the treatment of diabetic nephropathy
by: Kong Ling-li, et al.
Published: (2021-01-01)

WCN25-2470 Long-term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgAN
by: Vivekanand Jha, et al.
Published: (2025-02-01)

LAURENS Henry, L’Orient dans tous ses états. Orientales IV, CNRS éditions, 2017, 752 p.
by: Leyla Dakhli
Published: (2019-12-01)

WCN24-1268 End-Stage Kidney Disease (ESKD) and Chronic Kidney Disease (CKD) Progression among a Hispanic/Latino Population with Primary Immunoglobulin A Nephropathy (IgAN)
by: John Sim, et al.
Published: (2024-04-01)

Role of SGLT2 inhibitors in the treatment of visceral obesity
by: M. A. Druzhilov, et al.
Published: (2021-02-01)